Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study

Author:

Norori NataliaORCID,de Biase Chiara,Wong Yui Hang,Crabtree Sadie Robson,Cox Matt,Appleby Esther,Seggie Andrew,Brown Rachel,Rylance Amy

Abstract

Background The UK has an informed choice testing policy for prostate cancer. The prostate-specific antigen (PSA) blood test is available for free to any man aged ≥50 years who requests it and has been informed of the harms and benefits. This policy leads to differences in PSA testing rates, which can exacerbate health inequalities. Aim To assess whether Prostate Cancer UK’s risk checker helps men at risk of prostate cancer make an informed choice about the PSA test. Design & setting Mixed-methods study in the UK. Method In total, 1181 men at risk, their partners, and clinical experts participated in surveys, focus groups, and one-to-one interviews. Data on risk checker completions by sociodemographic factors were analysed over time. Data from general practices that sent the risk checker to their patients were collected and analysed for service monitoring purposes. Results There was a strong assumption that testing must be good, and therefore a need to emphasise the pros and cons of the test and that having it was the patient’s decision. Men believed their GP would invite them for PSA testing. On the impact of the risk checker, 79.6% of men who completed it had at least one prostate cancer risk factor; the average time they interacted with the information in the tool was 9 minutes 28 seconds; and 75.7% felt the tool had equipped them to make an informed choice. Conclusion Online decision-making tools, such as the risk checker, can help reach men at high risk of prostate cancer and support them in making an informed choice about the PSA test.

Publisher

Royal College of General Practitioners

Reference11 articles.

1. Prostate Cancer UK (2022) About prostate cancer. accessed. https://prostatecanceruk.org/prostate-information-and-support/risk-and-symptoms/about-prostate-cancer. 13 Jun 2024.

2. UK National Screening Committee (2020) Prostate cancer. accessed. https://view-health-screening-recommendations.service.gov.uk/prostate-cancer. 13 Jun 2024.

3. Pubic Heath Engand (2016) Prostate cancer risk management programme: overview. accessed. https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-overview. 19 Jun 2024.

4. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit

5. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3